Figure 1
Figure 2
Figure 3
The antibodies against measles, mumps and rubella by age group in the measles outbreak, May–October 2018, the Michalovce and Sobrance districts in the Košice region, Slovakia (n=102)_
| Positive and cut-off values (n=102) (%) | |||||||
|---|---|---|---|---|---|---|---|
| Characteristic | 0 | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-34 |
| All cases | 23 | 45 | 12 | 13 | 7 | 2 | 102 |
| MEASLES | |||||||
| IgM n=68 | 13 (12.7) | 31 (30.4) | 8 (7.8) | 11 (10.8) | 4 (3.9) | 1 (1.0) | 68 (66.7) |
| IgG n=23 | 1 (1.0) | 7 (6.9) | 3 (2.9) | 4 (3.9) | 6 (5.9) | 2 (2.0) | 23 (22.5) |
| MUMPS | |||||||
| IgG n=60 | 10 (9.8) | 28 (27.5) | 8 (7.8) | 6 (5.9) | 6 (5.9) | 2 (2.0) | 60 (58.8) |
| RUBELLA | |||||||
| IgG n=20 | 2 (2.0) | 3 (2.9) | 3 (2.9) | 4 (3.9) | 6 (5.9) | 2 (2.0) | 20 (19.6) |
| Positive antibodies against rubella and the type of applied combination vaccines (n=20) (%) | |||||||
| MMR+MMR | 2 (10.0) | 3 (15.0) | 3 (15.0) | 1 (5.0) | 0 | 0 | 9 (45.0) |
| MM+MMR | 0 | 0 | 0 | 3 (15.0) | 1 (5.0) | 0 | 4 (20.0) |
| Mo+Mo | 0 | 0 | 0 | 0 | 5 (25.0) | 2 (10.0) | 7 (35.0) |
| TOTAL | 2 (10.0) | 3 (15.0) | 3 (15.0) | 4 (20.0) | 6 (30.0) | 2 (10.0) | 20 (100.0) |
| Negative antibodies against rubella and the type of applied combination vaccines (n=82) (%) | |||||||
| MMR+MMR MMR+MMR: two doses of trivalent vaccine against measles, mumps and rubella | 21 (25.6) | 42 (51.2) | 9 (11.0) | 9 (11.0) | 0 | 0 | 81 (98.8) |
| MM+MMR MM+MMR: one dose of bivalent measles-mumps vaccine, and one dose of trivalent measles-mumps-rubella vaccine | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mo+Mo Mo+Mo: two doses of monovalent vaccine against measles | 0 | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (1.2) |
| TOTAL | 21 (25.6) | 42 (51.2) | 9 (11.0) | 9 (11.0) | 1 (1.2) | 0 | 82 (100.0) |
Characteristics of all patients (n=439) and of patients vaccinated with two MCV doses (n=102) in the measles outbreak in Michalovce and Sobrance districts, Slovak Republic 2018_
| Characteristics of all patients in the measles outbreak, the Michalovce and Sobrance districts (n=439) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age group | ||||||||||
| Characteristic | 0 | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | TOTAL |
| Males | 33 | 27 | 30 | 35 | 38 | 16 | 19 | 10 | 4 | 212 |
| Females | 48 | 33 | 42 | 30 | 38 | 13 | 12 | 8 | 3 | 227 |
| TOTAL (%) | 81 (18.5) | 60 (13.7) | 72 (16.4) | 65 (14.8) | 76 (17.3) | 29 (6.6) | 31 (7.1) | 18 (4.1) | 7 (1.6) | 439 (100.0) |
| Hospitalized | 72 (16.4) | 51 (11.6) | 52 (11.8) | 31 (7.1) | 47 (10.7) | 18 (4.1) | 13 (3.0) | 2 (0.5) | 2 (0.5) | 288 (65.6) |
| Complications | 10 (2.3) | 8 (1.8) | 6 (1.4) | 2 (0.5) | 8 (1.8) | 1 (0.2) | 3 (0.7) | 0 | 1 (0.2) | 39 (8.9) |
| VACCINATION STATUS (%) (n=439) | ||||||||||
| MCV1 | ||||||||||
| MMR TRIMOVAX, PRIORIX, M-M-RVAXPRO | 0 | 21 (4.8) | 58 (13.2) | 15 (3.4) | 13 (3.0) | 10 (2.3) | 6 (1.4) | 0 | 0 | 123 (28.0) |
| MM MOPAVAC | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.2) | 0 | 0 | 1 (0.2) |
| Mo MOVIVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (0.5) | 1 (0.2) | 3 (0.7) |
| All MCV1 | 0 | 21 (4.8) | 58 (13.2) | 15 (3.4) | 13 (3.0) | 10 (2.3) | 7 (1.6) | 2 (0.5) | 1 (0.2) | 127 (28.9) |
| MCV2 | ||||||||||
| MMR TRIMOVAX, PRIORIX, M-M-RVAXPRO | 0 | 0 | 0 | 37 (8.4) | 52 (11.8) | 17 (3.9) | 10 (2.3) | 2 (0.5) | 0 | 118 (26.9) |
| MM MOPAVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.2) | 0 | 1 (0.2) |
| Mo MOVIVAC | 0 | 0 | 0 | 0 | 0 | 0 | 9 (2.1) | 7 (1.6) | 2 (0.5) | 18 (4.1) |
| All MCV2 | 0 | 0 | 0 | 37 (8.4) | 52 (11.8) | 17 (3.9) | 19 (4.3) | 10 (2.3) | 2 (0.5) | 137 (31.2) |
| All vaccinated | 0 | 21 (4.8) | 58 (13.2) | 52 (11.8) | 65 (14.8) | 27 (6.2) | 26 (5.9) | 12 (2.7) | 3 (0.7) | 264 (60.1) |
| Unvaccinated | 0 | 23 (5.2) | 14 (3.2) | 12 (2.7) | 5 (1.1) | 1 (0.2) | 0 | 0 | 3 (0.7) | 58 (13.2) |
| Unvaccinated for age | 81 (18.5) | 16 (3.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97 (22.1) |
| All unvaccinated | 81 (18.5) | 39 (8.9) | 14 (3.2) | 12 (2.7) | 5 (1.1) | 1 (0.2) | 0 | 0 | 3 (0.7) | 155 (35.3) |
| Unknown | 0 | 0 | 0 | 1 (0.2) | 6 (1.4) | 1 (0.2) | 5 (1.1) | 6 (1.4) | 1 (0.2) | 20 (4.6) |
| Characteristics of patients vaccinated with 2 MCV doses in the measles outbreak in the Michalovce and Sobrance districts (n=102) | ||||||||||
| Males | 0 | 0 | 0 | 13 | 22 | 7 | 6 | 4 | 1 | 53 |
| Females | 0 | 0 | 0 | 10 | 23 | 5 | 7 | 3 | 1 | 49 |
| TOTAL (%) | 0 | 0 | 0 | 23 (22.5) | 45 (44.1) | 12 (11.8) | 13 (12.8) | 7 (6.9) | 2 (2.0) | 102 (100.0) |
| VACCINATION STATUS (%) (n=102) | ||||||||||
| MCV1 | ||||||||||
| MMR TRIMOVAX, PRIORIX, M-M-RVAXPRO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MM MOPAVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mo MOVIVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| All MCV1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MCV2 | ||||||||||
| MMR TRIMOVAX, PRIORIX, M-M-RVAXPRO | 0 | 0 | 0 | 23 (22.5) | 45 (44.1) | 12 (11.8) | 13 (12.7) | 0 | 0 | 93 (91.2) |
| MM MOPAVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mo MOVIVAC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 (6.9) | 2 (2.0) | 9 (8.8) |
| All MCV2 | 0 | 0 | 0 | 23 (22.5) | 45 (44.1) | 12 (11.8) | 13 (12.7) | 7 (6.9) | 2 (2.0) | 102 (100.0) |